Clinical Trial Update: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing durvalumab with low-dose prophylactic cranial irradiation (PCI) versus durvalumab with observation in radically treated stage III non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Association NVALT Studies | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING